EZH2 and myelodysplastic syndrome: Analyzing the expression levels of EZH2 in pediatric patients with MDS and the evolution of disease, we observed that the low expression group presented evolution of the disease in 100% of the cases, the intermediate expression group showed disease evolution in 4.34% patients, and in the high expression group, 63.63% patients showed evolution from MDS to AML.